Practice & Policy

FDA Pulls Tanning Age-Restriction Rule; TanPrevent Pilot Aims to Fill the Gap

<![CDATA[TanPrevent and the Case for Preventing Thousands of Melanomas]]>
Pexels / pixabay

On March 16, 2026, the FDA withdrew its 2015 proposed rule that would have banned UV sunlamp use for anyone under 18 and required users to acknowledge the risks before each session. The withdrawal leaves a wide-open prevention gap: indoor tanning remains a proven, avoidable source of carcinogenic UV exposure, and youth access remains problematic. Evidence of harm, it turns out, does not guarantee the measures needed to reduce exposure.

That gap is the reason TanPrevent exists. TanPrevent.org, developed by the Indoor Tanning Prevention Working Group, brings researchers and clinicians together to tackle misconceptions and to connect education with practical support — avoiding first use, stopping tanning, and sustaining that change.

Why is quitting tanning so hard for some patients?

The numbers are small but telling. In a college-campus study, 16 of 296 participants met research criteria for tanning dependence, assessed through loss of control, unsuccessful attempts to cut down, and continued use despite harm. That's roughly 5% of a screened campus population. Clinicians should ask patients directly about tanning parlor use, previous quit attempts, and what made those attempts difficult.

The biology may matter here. In mice, repeated UV exposure activated a keratinocyte p53–proopiomelanocortin pathway, raised skin-derived β-endorphin, and produced opioid-mediated dependence. A blinded crossover study of 7 frequent tanners found increased blood flow in reward-associated brain regions after UV versus sham exposure. The human pilot doesn't confirm the mouse mechanism in people, but it makes reinforcement a serious concern and a priority for future research.

What does the cessation evidence show?

In a randomized trial of 265 young women who screened positive for tanning addiction, more participants receiving tailored mobile messages reported quitting at treatment completion than those receiving standard risk education. But the groups did not differ significantly at 3 months. Translation: engagement works short-term; durability is the unsolved problem. Future interventions need to learn what drives sustained cessation rather than a return to use.

How would the clinical pilot work?

The current plan starts at one school or campus. Dermatologists and other clinicians would test a brief conversation guide covering tanning behavior, motivations, previous quit attempts, and readiness to change, with planned follow-up built in. Medical students would help develop patient-facing materials and evaluate the project.

Through a campus partnership, students could produce source-checked videos and peer discussions, built with young people and clinical mentors. The materials would push toward specific decisions: declining a first session, or seeking support after a relapse.

The initiative also has a policy arm:

  • Dermatology societies would connect mentors with participating sites and supply educational resources.
  • Verified policy briefs would go to legislators and public health partners.
  • The Derm Policy Network would help medical students compile state age limits, consent exceptions, and facility oversight, with policy experts checking interpretations — feeding TanPrevent's developing Policy Observatory.

One caveat the authors flag clearly: cosmetic indoor tanning must stay distinct from medically supervised phototherapy.

Who is being reached — and who drops out?

Equity questions remain open. A state-level melanoma analysis found higher age-standardized mortality in states with a lower sociodemographic index, despite similar incidence. The analysis didn't assess indoor tanning or explain those differences. TanPrevent should therefore evaluate who participates, who is lost to follow-up, whether cessation lasts, and whether indoor tanning is simply replaced by outdoor tanning.

The authors — Hossein Akbarialiabad, MD, MSc, HMBA, an internal medicine resident with a research affiliation in the Department of Dermatology at Oregon Health & Science University, and Jane M. Grant-Kels, MD, professor of dermatology, pathology, and pediatrics and director of the Cutaneous Oncology Center and Melanoma Program at UConn Health — invite clinicians, medical students, researchers, and dermatology societies to join TanPrevent.org. The next concrete step is launching the single-campus pilot and tracking whether cessation holds beyond the three-month mark where prior interventions have faltered.

Source: dermatologytimes.com

Share this article:

Sophie Lindqvist

Show full bio

Market editor covering people, launches and day-to-day practice in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.

More from Sophie Lindqvist →

Related articles

« Previous articleNext article »